Louvain-la-Neuve, Belgium, October 3, 2024 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, is pleased to announce that the European Commission has approved the financing of the Accelerate.EU project launching on October 1, 2024. IBA’s key role in this new project further reiterates its market leading role in supporting the production of novel targeted alpha therapies for cancer.
As the industry leader of the Accelerate.EU initiative, IBA will facilitate the development of a production network to enable greater access to targeted alpha therapy across the EU through the development of a new alpha-machine cyclotron as an in-kind contribution. IBA will also work in close collaboration with the Jules Bordet Institute, the academic and clinical Accelerate.EU coordinator, to manage the project.
The Accelerate.EU project, a groundbreaking EUR 16 million initiative, has been officially launched with the ambitious goal of establishing a resilient and strategic European autonomy in alpha therapies. This five-year project aims to enhance patient access to cutting-edge cancer treatments by creating a complete value chain for the production and clinical application of the alpha-emitting isotope Astatine-211 (211At).
Ad Statistics
Times Displayed: 16670
Times Visited: 376 GE HealthCare’s Repair Center Solutions are an ideal complement to your in-house service team. We service a broad range of mobile devices, including monitors and cardiology devices, parts, and portable ultrasound systems and probes.
The project has secured EUR 8 million in funding from the European Commission under the Innovative Health Initiative (IHI), matched by an equivalent in-kind contribution from industry partners. This collaboration brings together 17 leading European institutions and companies across 9 countries, blending academic expertise with industrial innovation.
The Accelerate.EU project is set to transform the landscape of cancer care by pioneering the development of novel radiotheranostic solutions to address unmet clinical needs. At the heart of this initiative is 211At, a highly promising alpha-emitting radioisotope with the potential to treat aggressive cancers such as triple-negative breast cancer, pancreatic cancer, and glioblastoma. The project will focus on developing and testing new therapeutic agents, ensuring a robust and sustainable infrastructure for 211At production and treatment.
“By integrating the entire value chain — from bench to bedside — Accelerate.EU aims to streamline the supply of 211At across Europe, ensuring that patients have timely access to this innovative treatment. The project will also explore co-clinical approaches, where clinical studies run in parallel with preclinical studies, enhancing the ability to identify patients who are most likely to benefit from 211At therapy. The Accelerate.EU project is a significant step forward in cancer research.”said Hugo Levillain, PhD, Project Lead Coordinator at Institute Jules Bordet.
